REFERENCES
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol 2015;49:690-6.
3. Pais R, Barritt AS 4th, Calmus Y, et al. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol 2016;65:1245-57.
4. Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol 2016;65:425-43.
5. Ratziu V, Charlotte F, Heurtier A, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
6. Ozturk A, Grajo JR, Gee MS, et al. Quantitative hepatic fat quantification in non-alcoholic fatty liver disease using ultrasound-based techniques: a review of literature and their diagnostic performance. Ultrasound Med Biol 2018;44:2461-75.
7. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265-73.
8. Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics (Basel) 2021;11:98.
9. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265-9.
10. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740-51.
11. Doycheva I, Shaker M, Allende D, Lopez R, Watt KD, Alkhouri N. Low utility of noninvasive fibrosis scores in young adults with nonalcoholic fatty liver disease. Am J Gastroenterol 2017;112:652-3.
12. Castera L. Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics. Liver Int 2020;40 Suppl 1:77-81.
13. Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2016;111:677-84.
14. Chang PE, Goh GB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther 2016;7:91-106.
15. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717-30.
16. Şirli R, Sporea I, Deleanu A, et al. Comparison between the M and XL probes for liver fibrosis assessment by transient elastography. Med Ultrason 2014;16:119-22.
17. Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343-52.
18. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362-73.
19. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
20. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739-52.
21. Ampuero J, Aller R, Gallego-Durán R, et al. HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70.
22. Gunn NT, Shiffman ML. The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom. Clin Liver Dis 2018;22:109-19.
23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
24. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703.
25. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
26. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77.
27. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-35.e4.
28. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
29. Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol 2018;68:519-25.
30. Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name. J Hepatol 2018;68:391-2.
31. El Atrache MM, Abouljoud MS, Divine G, et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant 2012;26:E505-12.
32. Henry ZH, Argo CK. How to identify the patient with nonalcoholic steatohepatitis who will progress to cirrhosis. Gastroenterol Clin North Am 2020;49:45-62.
33. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
34. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
35. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012;55:447-54.
37. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013;33:1398-405.
38. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003;41:269-78.
39. Francoz C, Sola E. Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter. J Hepatol 2019;70:828-30.
40. Yoo JJ, Kim SG, Kim YS, et al. Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex. J Hepatol 2019;70:847-54.
41. Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014;59:1772-8.
42. Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011). J Hepatol 2015;63:486-93.
43. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 2017;66:123-31.
44. Formica RN, Aeder M, Boyle G, et al. Simultaneous liver-kidney allocation policy: a proposal to optimize appropriate utilization of scarce resources. Am J Transplant 2016;16:758-66.
45. Nadelson J, Satapathy SK, Nair S. Glycated hemoglobin levels in patients with decompensated cirrhosis. Int J Endocrinol 2016;2016:8390210.
46. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-61.
47. English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia 2015;58:1409-21.
48. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.e1.
49. Tayob N, Lok AS, Do KA, Feng Z. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol 2016;14:469-475.e2.
50. Olivares-Gazca JC, Nuñez-Cortes AK, Mendez-Huerta MA, Cantero-Fortiz Y, Orea-Martinez JG, Ruiz-Argüelles GJ. More on the thrombocytopenia of the non-alcoholic fatty liver disease. Hematology 2017;22:316-9.
51. López-Trujillo MA, Olivares-Gazca JM, Cantero-Fortiz Y, et al. Nonalcoholic fatty liver disease and thrombocytopenia III: its association with insulin resistance. Clin Appl Thromb Hemost 2019;25:1076029619888694.
52. Panke CL, Tovo CV, Villela-Nogueira CA, et al. Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis. Ann Hepatol 2020;19:88-91.
53. Yoneda M, Fujii H, Sumida Y, et al. Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011;46:1300-6.
54. Habib A, Mihas A, Abouassi S, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol 2005;3:286-91.
55. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 2015;1852:1765-78.
57. Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res 2014;103:341-9.
58. Florén CH, Chen CH, Franzén J, Albers JJ. Lecithin: cholesterol acyltransferase in liver disease. Scand J Clin Lab Invest 1987;47:613-7.
59. Chang L, Clifton P, Barter P, Mackinnon M. High density lipoprotein subpopulations in chronic liver disease. Hepatology 1986;6:46-9.
60. Trifan A, Chiriac S, Stanciu C. Update on adrenal insufficiency in patients with liver cirrhosis. World J Gastroenterol 2013;19:445-56.
61. Jang JY, Kim TY, Sohn JH, et al. Relative adrenal insufficiency in chronic liver disease: its prevalence and effects on long-term mortality. Aliment Pharmacol Ther 2014;40:819-26.
62. Piano S, Favaretto E, Tonon M, et al. Including relative adrenal insufficiency in definition and classification of acute-on-chronic liver failure. Clin Gastroenterol Hepatol 2020;18:1188-96.e3.
63. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004;99:1316-20.
64. Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003;48:2173-81.
65. Vuppalanchi R, Gould RJ, Wilson LA, et al. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012;6:379-85.
66. Zhou YJ, Zheng KI, Ma HL, et al. Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. Nutr Metab Cardiovasc Dis 2021;31:552-60.
68. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8.
69. Kowdley KV, Belt P, Wilson LA, et al. NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77-85.
70. Licata A, Nebbia ME, Cabibbo G, et al. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009;15:2132-8.
71. Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009;49:887-900.
72. Walker NM, Stuart KA, Ryan RJ, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010;51:1683-91.
73. Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: hereditary hemochromatosis. Am J Gastroenterol 2019;114:1202-18.
74. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol 2009;15:4653-8.
75. Vassiliadis T, Mpoumponaris A, Vakalopoulou S, et al. Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: incidence and correlation with disease severity and survival. Hepatol Res 2010;40:161-70.
76. Andrès E, Serraj K, Zhu J, Vermorken AJ. The pathophysiology of elevated vitamin B12 in clinical practice. QJM 2013;106:505-15.
77. Arendt JF, Nexo E. Unexpected high plasma cobalamin : proposal for a diagnostic strategy. Clin Chem Lab Med 2013;51:489-96.
78. Wentworth B, Copland A. Revisiting vitamin B12 deficiency: A Clinician’s Guide For the 21st Century. Practical Gastroenterology 2018;XLII:28-49.
80. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010;44:208-13.
